Enanta Pharmaceuticals
Develops oral RSV antivirals and immunology drugs funded by AbbVie HCV royalties.
$13.60
After-hours close−0.03 (−0.22%)
At close$13.63(−1.23%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 94.80%27.57M sharesInsiders 4.67%1.36M sharesOther 0.53%153.6K shares
Shares outstanding 29.08M · Float 27.60M · 94.9% free float
Institutions13F, as of Jun 30, 2026
126 holders · 27.57M shares · 15 new positions · 62 increased · 37 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 3.65M | 12.57% | +3.65Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 3.24M | 11.16% | +140.7K | Aug 7, 2026 |
| Krensavage Asset Management, LLC | 2.87M | 9.86% | 0 | Aug 14, 2026 |
| Farallon Capital Management LLC | 2.42M | 8.32% | −453.7K | Aug 14, 2026 |
| Deep Track Capital, LP | 1.44M | 4.97% | −512.7K | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 1.34M | 4.62% | +1.29M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.21M | 4.17% | +33.7K | Aug 13, 2026 |
| Spruce Street Capital LP | 1.09M | 3.74% | +156.1K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 12.10% | 3.49M | 13G | Nov 7, 2025 ↗ |
| BlackRock, Inc. | 7.80% | 1.67M | 13G | Apr 17, 2025 ↗ |
| Jay R. Luly, Ph.D. | 7.70% | 1.70M | 13D | Feb 14, 2025 ↗ |
| Deep Track Capital, LP | 6.78% | 1.96M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jay R. Luly | director, officer: President and CEO | 862.8K | 2.97% | Feb 13, 2026 |
| Yat Sun Or | officer: Chief Scientific Officer | 373.0K | 1.28% | Feb 13, 2026 |
| Brendan Luu | officer: Chief Business Officer | 39.9K | 0.14% | Feb 13, 2026 |
| Tara Lynn Kieffer | officer: Chief Product Strategy Officer | 32.2K | 0.11% | Feb 13, 2026 |
| Scott T. Rottinghaus | officer: Chief Medical Officer | 23.8K | 0.08% | Aug 10, 2026 |
| Harry R. III Trout | officer: See Remarks | 16.3K | 0.06% | Dec 5, 2025 |
| Kathleen S. Capps | officer: See Remarks | 8.4K | 0.03% | Dec 5, 2025 |
| Matthew Paul Kowalsky | officer: Chief Legal Officer | 1.3K | 0.00% | Feb 13, 2026 |
3 ten-percent owners hold 1.89M shares by Form 4, outside the officers-and-directors figure above · 11 people have not refiled in the last 18 months (1.18M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Dec 5, 2025 | Jay R. Lulydirector, officer: President and CEO | Sale | 4,743 | $14.23 | 858,026 |
| Dec 5, 2025 | Yat Sun Orofficer: Chief Scientific Officer | Sale | 2,390 | $14.23 | 371,392 |
| Dec 5, 2025 | Tara Lynn Kiefferofficer: Chief Product Strategy Officer | Sale | 2,106 | $14.23 | 30,620 |
| Dec 5, 2025 | Brendan Luuofficer: Chief Business Officer | Sale | 1,394 | $14.23 | 38,329 |
| Dec 5, 2025 | Scott T. Rottinghausofficer: Chief Medical Officer | Sale | 798 | $14.23 | 21,792 |
| Dec 5, 2025 | Harry R. III Troutofficer: See Remarks | Sale | 542 | $14.23 | 16,348 |
| Dec 5, 2025 | Kathleen S. Cappsofficer: See Remarks | Sale | 323 | $14.23 | 8,377 |
| Dec 2, 2025 | Harry R. III Troutofficer: See Remarks | Sale | 380 | $13.96 | 16,890 |
| Dec 2, 2025 | Kathleen S. Cappsofficer: See Remarks | Sale | 207 | $13.96 | 8,700 |
CongressHouse and Senate disclosures
Not reported.